Optical Image-Guided Cancer Therapy

Author(s): Lihong Bu, Xiaowei Ma, Yingfeng Tu, Baozhong Shen, Zhen Cheng

Journal Name: Current Pharmaceutical Biotechnology

Volume 14 , Issue 8 , 2013

Become EABM
Become Reviewer
Call for Editor


Optical molecular imaging holds great promise for image guiding cancer therapy. The non-invasive guidance of therapeutic strategies would enable the removal of cancerous tissue while avoiding side effects and systemic toxicity, preventing damage of healthy tissues and decreasing the risk of postoperative problems. This review article highlights the advantages and disadvantages of the optical imaging techniques that are currently available, including their recent applications in image-guided cancer therapy. Three approaches for optical image-guided cancer therapy were discussed in this review, namely, bioluminescence imaging (BLI), fluorescence imaging (FI) and Cerenkov luminescence imaging (CLI). BLI is always used in small animal imaging for the in vivo tracking of therapeutic gene expression and cell-based therapy. To the contrary, FI display high promising for clinical translation. The applications of FI include image-guided surgery, radiotherapy, gene therapy, drug delivery and sentinel lymph node fluorescence mapping. CLI is a novel radioactive optical hybrid imaging strategy and its use for animal and clinical translation was also discussed. Perspectives on the translation of optical image-guided cancer therapy into clinical practice were provided.

Keywords: Bioluminescence imaging (BLI), Cerenkov luminescence imaging, Fluorescence imaging, Image-guided cancer therapy, Molecular imaging, Optical imaging.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 22 January, 2014
Page: [723 - 732]
Pages: 10
DOI: 10.2174/1389201014666131226112507
Price: $65

Article Metrics

PDF: 42